PTC THERAPEUTICS, INC.

PTCT

PTC THERAPEUTICS, INC.

PTCT

Insider Sentiment (TTM):

Last Purchase:2023-12-12Last Sale:2026-06-26Shares Purchased (TTM):0Shares Sold (TTM):669,936

Institutional Sentiment:

As of:2026-03-31Institutional Shares Owned:92,608,246Shares Outstanding:82,521,023Institutional Ownership Pct.:112.22%

Earnings Market Reaction:

Filing Date:2026-07-30Price on Filing Date:N/APrevious Close:N/A% Change:N/A

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Financial Statements

10‑Q10‑K

Values in Millions ($)	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Assets
Assets Current
Cash And Cash Equivalents At Carrying Value	1,050	834	985	673	1,017	1,480	780	526	655	548	594	165
Marketable Securities Current	1,179	1,058	961	1,015	972	547	360	487	439	336	283	130
Receivables Net Current	239	220	182	203	196	210	159	200	187	198	161	166
Inventory Net	91	76	80	53	34	22	23	36	32	30	31	36
Prepaid Expense And Other Assets Current	58	66	67	64	54	57	44	33	46	56	150	44
Assets Current	2,617	2,254	2,274	2,008	2,273	2,316	1,366	1,282	1,358	1,169	1,219	540
Property Plant And Equipment Net	51	53	55	57	57	59	61	63	66	93	87	85
Intangible Assets Net Excluding Goodwill	403	381	389	396	144	118	119	330	330	330	379	423
Goodwill	82	82	82	82	82	82	82	82	82	82	82	82
Operating Lease Right Of Use Asset	75	77	80	81	56	57	57	59	57	91	92	94
Assets	3,250	2,869	2,899	2,644	2,634	2,655	1,705	1,842	1,916	1,790	1,896	1,260
Liabilities And Stockhold…
Liabilities Current
Accounts Payable And Accrued Liabilities Current	382	313	381	303	339	318	304	336	339	331	392	371
Long Term Debt Current	55	287	287	286	-	-	-	-	-	-	-	-
Contract With Customer Liability Current	1	0	2	2	10	13	6	-	-	-	1	1
Operating Lease Liability Current	12	12	12	12	12	11	10	14	14	15	13	12
Finance Lease Liability Current	6	6	3	3	5	5	3	3	2	2	3	3
Liabilities Current	771	924	968	866	628	595	581	611	610	575	603	492
Long Term Debt Noncurrent	536	-	-	-	286	286	285	285	285	285	284	573
Operating Lease Liability Noncurrent	88	90	94	95	71	74	75	83	79	105	98	100
Business Combination Contingent Consideration Liab…	-	-	-	-	-	0	1	22	21	36	36	39
Deferred Income Tax Liabilities Net	-	-	-	-	-	-	-	56	56	56	56	52
Finance Lease Liability Noncurrent	-	-	3	14	14	14	16	16	16	16	17	17
Other Liabilities Noncurrent	15	14	14	3	8	22	21	0	0	0	0	0
Liabilities	3,416	3,050	3,104	2,799	2,841	2,841	2,803	2,897	2,897	2,684	2,714	1,931
Stockholders Equity
Common Stock Value	0	0	0	0	0	0	0	0	0	0	0	0
Additional Paid In Capital	2,712	2,778	2,748	2,667	2,631	2,608	2,575	2,531	2,511	2,487	2,466	2,447
Accumulated Other Comprehensive Income Loss Net Of…	6	8	11	6	7	-14	-26	-4	-16	-6	-1	10
Retained Earnings Accumulated Deficit	-2,884	-2,967	-2,964	-2,829	-2,845	-2,780	-3,647	-3,581	-3,474	-3,375	-3,284	-3,128
Stockholders Equity	-165	-180	-205	-156	-207	-186	-1,098	-1,054	-980	-894	-819	-671
Liabilities And Stockholders Equity	3,250	2,869	2,899	2,644	2,634	2,655	1,705	1,842	1,916	1,790	1,896	1,260
Common Stock Par Or Stated Value Per Share	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001
Common Stock Shares Authorized	250	250	250	250	250	250	250	250	250	250	250	250
Common Stock Shares Issued	83	83	81	80	79	79	78	77	77	77	76	75
Shares Outstanding	83	83	81	80	79	79	78	77	77	77	76	75

Subscribe to unlock 17+ years of financial data, unlimited metrics, and saved tables

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables

Start free trial

Custom Table

10‑Q10‑K

0/5

Search a metric to start building a table

Subscribe to unlock 17+ years of financial data, unlimited metrics, transformations, and saved visuals

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals

Start free trial

Interactive Financial Visualizations

10‑Q10‑K

Stock Price:

OnOff

Transformations:

0/1

Search a metric to start building a visual

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Earnings Market Reaction

10‑Q10‑K

Fiscal Year	Q1 1 Month	Q1 2 Month	Q1 3 Month	Q2 1 Month	Q2 2 Month	Q2 3 Month	Q3 1 Month	Q3 2 Month	Q3 3 Month	Q4 1 Month	Q4 2 Month	Q4 3 Month
2026	14.51%	30.92%	19.12%	-	-	-	-	-	-	-	-	-
2025	34.07%	37.72%	23.63%	-2.05%	17.14%	31.85%	26.98%	16.01%	11.12%	-7.74%	-1.73%	5.42%
2024	29.84%	40.49%	30.52%	8.84%	15.75%	25.58%	2.14%	5.28%	8.12%	12.99%	-6.29%	-9.02%
2023	-	-	-	-1.49%	-40.67%	-42.44%	-14.57%	18.54%	14.11%	3.19%	-10.18%	17.40%
Earnings Market Reaction data beyond 3 years is for subscribers only. Unlock the full earnings market reaction history Start 7-day free trial

Subscribe to unlock 17+ years of financial data and 90+ calculated metrics

Start 7-day free trial

Subscribe to unlock 17+ years of data and 90+ calculated metrics

Start free trial

Performance and Valuation Metrics

Rows marked with a lock icon are subscribers only — subscribe to unlock 90+ calculated metrics and 17+ years of history.

Metrics	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Liquidity Ratios
Current Ratio	3.39	2.44	2.35	2.32	3.62	3.89	2.35	2.10	2.23	2.03	2.02	1.10
Quick Ratio	3.20	2.29	2.20	2.18	3.48	3.76	2.23	1.99	2.10	1.88	1.72	0.94
Working Capital	1.85B	1.33B	1.31B	1.14B	1.65B	1.72B	784.55M	670.84M	748.11M	594.19M	615.53M	48.24M
Leverage & Debt
Debt to Equity	-20.66	-16.90	-15.12	-17.97	-13.75	-15.29	-2.55	-2.75	-2.96	-3.00	-3.32	-2.88
Interest Coverage TTM	0.68	-0.35	5.69	5.62	4.88	4.45	-1.81	-0.79	-1.26	-2.57	-3.40	-5.90
Debt Ratio	1.05	1.06	1.07	1.06	1.08	1.07	1.64	1.57	1.51	1.50	1.43	1.53
Efficiency & Turnover
Asset Turnover TTM	0.34	0.30	0.75	0.79	0.78	0.80	0.45	0.58	0.55	0.55	0.52	0.56
Days Sales Outstanding TTM	78.73	94.97	35.87	41.34	39.63	42.02	72.25	74.10	73.91	78.61	61.58	66.35
Receivables Turnover TTM	4.64	3.84	10.18	8.83	9.21	8.69	5.05	4.93	4.94	4.64	5.93	5.50
Per Share Metrics
Diluted EPS TTM	-0.42	-2.26	7.73	8.63	8.05	6.89	-4.73	-5.89	-6.25	-7.57	-8.37	-8.51
Free Cash Flow Per Share TTM	-0.48	-2.74	8.83	8.99	8.93	8.68	-1.68	-2.61	-1.88	-1.12	-2.50	-3.39
Dividend Per Share TTM	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Margin Metrics
Operating Profit Margin TTM	12.45%	-7.05%	50.09%	43.61%	40.70%	40.23%	-37.50%	-14.92%	-21.99%	-39.60%	-46.86%	-80.89%
Net Profit Margin TTM	-3.80%	-22.58%	39.44%	42.25%	35.65%	33.55%	-45.03%	-50.32%	-53.25%	-62.45%	-66.81%	-80.40%
Growth Metrics
Net Revenue Growth (1Y)	-42.84%	-53.34%	114.51%	97.54%	96.00%	91.12%	-13.97%	12.84%	9.98%	20.39%	34.20%	14.58%
Net Income Growth (1Y)	-106.10%	-131.39%	-287.90%	-265.87%	-231.21%	-202.70%	-42.02%	-29.38%	-22.41%	1.40%	12.09%	20.76%
EPS Growth (1Y)	-105.74%	-129.72%	-281.55%	-262.60%	-228.82%	-200.57%	-43.54%	-30.80%	-24.43%	-2.27%	7.43%	14.79%
Valuation Metrics
P/E TTM	-176.41	-30.11	8.85	6.41	6.07	6.69	-9.55	-6.30	-4.89	-3.84	-3.29	-2.63
P/B TTM	-40.95	-31.15	-29.43	-30.92	-18.48	-21.43	-3.16	-2.71	-2.39	-2.49	-2.52	-2.52
P/S TTM	6.71	6.80	3.49	2.71	2.16	2.25	4.30	3.17	2.61	2.40	2.20	2.12
Market Cap	6.77B	5.62B	6.04B	4.82B	3.82B	3.98B	3.47B	2.85B	2.35B	2.23B	2.06B	1.69B
Enterprise Value	6.30B	5.06B	5.34B	4.43B	3.08B	2.78B	2.96B	2.60B	1.96B	1.95B	2.38B	2.08B
Calculated Values
Free Cash Flow TTM	-39.78M	-226.28M	702.34M	705.21M	697.51M	678.27M	-128.94M	-201.02M	-144.39M	-85.92M	-186.86M	-255.59M
Net Debt	-469.36M	-557.50M	-705.70M	-383.47M	-741.70M	-1.21B	-506.90M	-252.04M	-381.44M	-278.16M	316.43M	394.38M
Per-Share and Margin
EPS TTM
Adjusted EPS TTM
Cash Flow Per Share TTM
Pretax Margin TTM
Stock Comp to Revenue TTM
Turnover Ratios and Averages
Average Assets
Average Equity
Average Inventory
Average Receivables
Average Accounts Payables
Inventory Turnover TTM
Payables Turnover TTM
Days Inventory Outstanding TTM
Days Payables Outstanding TTM
Cash Conversion Cycle TTM
Working Capital to Revenue
Deferred Revenue to Revenue
Growth Rates
Total Assets Growth (1Y)
Total Assets Growth (3Y)
Total Assets Growth (5Y)
Dividends Paid Growth (1Y)
Dividends Paid Growth (3Y)
Dividends Paid Growth (5Y)
EPS Growth (3Y)
EPS Growth (5Y)
Net Income Growth (3Y)
Net Income Growth (5Y)
Net Profit Margin Growth (1Y)
Net Profit Margin Growth (3Y)
Net Profit Margin Growth (5Y)
Net Revenue Growth (3Y)
Net Revenue Growth (5Y)
Deferred Revenue Growth (1Y)
Retained Earnings Growth (1Y)
Credit, Liquidity, Returns, Payout
Cash Ratio
Net Working Capital
Debt to EBITDA TTM
Net Debt to EBITDA TTM
Net Debt to Equity
Altman A
Altman B
Altman C
Altman D
Altman E
Altman Z-Score
ROA TTM
ROE TTM
NOPAT TTM
ROIC TTM
Effective Tax Rate TTM
Payout Ratio TTM
Dilution Ratio
Retained Earnings to Equity
Treasury Stock to Equity
Treasury Stock Change (1Y)
Accrued to Current Liabilities
NCAV
NCAV Per Share TTM
Valuation Ratios
P/CF TTM
PEG Ratio
Dividend Yield TTM
Free Cash Flow Yield TTM
EV EBITDA TTM
EV EBIT TTM
EV Revenue TTM
EV FCF TTM
Stock Compensation TTM
Adjusted Net Income TTM
Billings TTM
Total Debt
Invested Capital

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Insider Transactions

2026-06-26Sale

Owner: Almstead, Neil Gregory

Title: CHIEF TECHNICAL OPS OFFICER

Shares: 8,130

Price/Share: $85.24

Value: $693,001.20

Shares Owned: 60,137

Relationship: Officer

Ownership: Direct

2026-06-25Sale

Owner: Almstead, Neil Gregory

Title: CHIEF TECHNICAL OPS OFFICER

Shares: 20,960

Price/Share: $86.08

Value: $1,804,236.80

Shares Owned: 60,137

Relationship: Officer

Ownership: Direct

2026-06-22Sale

Owner: Almstead, Neil Gregory

Title: CHIEF TECHNICAL OPS OFFICER

Shares: 23,749

Price/Share: $80.91

Value: $1,921,531.59

Shares Owned: 60,137

Relationship: Officer

Ownership: Direct

2026-06-17Sale

Owner: Boulding, Mark Elliott

Title: EXEC. VP AND CLO

Shares: 10,462

Price/Share: $78.87

Value: $825,137.94

Shares Owned: 105,272

Relationship: Officer

Ownership: Direct

2026-06-17Sale

Owner: Utter, Christine Marie

Title: SVP, CHIEF ACCOUNTING OFFICER

Shares: 19,686

Price/Share: $75.56

Value: $1,487,474.16

Shares Owned: 70,199

Relationship: Officer

Ownership: Direct

Filed Date	Owner	Relationship	Title	Ownership	Purchase/Sale	No. Shares	Price Per Share	Value	Shares Owned	Document Type
2026-06-26	Almstead, Neil Gregory	Officer	CHIEF TECHNICAL OPS OFFICER	Direct	Sale	8,130	85.24	$693,001.20	60,137	4
2026-06-25	Almstead, Neil Gregory	Officer	CHIEF TECHNICAL OPS OFFICER	Direct	Sale	20,960	86.08	$1,804,236.80	60,137	4
2026-06-22	Almstead, Neil Gregory	Officer	CHIEF TECHNICAL OPS OFFICER	Direct	Sale	23,749	80.91	$1,921,531.59	60,137	4
2026-06-17	Boulding, Mark Elliott	Officer	EXEC. VP AND CLO	Direct	Sale	10,462	78.87	$825,137.94	105,272	4
2026-06-17	Utter, Christine Marie	Officer	SVP, CHIEF ACCOUNTING OFFICER	Direct	Sale	19,686	75.56	$1,487,474.16	70,199	4
2026-06-10	Pauwels, Eric	Officer	CHIEF BUSINESS OFFICER	Direct	Sale	21,277	75.00	$1,595,775.00	73,411	4
2026-05-15	Boulding, Mark Elliott	Officer	EXEC. VP AND CLO	Direct	Sale	2,812	72.38	$203,532.56	105,212	4
2026-05-14	Klein, Matthew B.	Director,Officer	CHIEF EXECUTIVE OFFICER	Direct	Sale	12,572	72.92	$916,750.24	393,998	4
2026-05-08	Boulding, Mark Elliott	Officer	EXEC. VP AND CLO	Direct	Sale	3,540	78.70	$278,598.00	105,212	4
2026-04-21	Klein, Matthew B.	Director,Officer	CHIEF EXECUTIVE OFFICER	Direct	Sale	2,850	70.91	$202,093.50	394,070	4
2026-04-06	Boulding, Mark Elliott	Officer	EXEC. VP AND CLO	Direct	Sale	2,265	69.33	$157,032.45	105,212	4
2026-04-02	Golden, Lee Scott	Officer	EVP & CHIEF MEDICAL OFFICER	Direct	Sale	829	67.99	$56,363.71	79,115	4
2026-04-01	Almstead, Neil Gregory	Officer	CHIEF TECHNICAL OPS OFFICER	Direct	Sale	52,003	69.56	$3,617,328.68	60,137	4
2026-03-12	Klein, Matthew B.	Director,Officer	CHIEF EXECUTIVE OFFICER	Direct	Sale	2,662	64.08	$170,580.96	396,920	4
2026-03-10	Okey, Stephanie	Director	-	Direct	Sale	15,167	70.00	$1,061,690.00	8,000	4
2026-03-05	Okey, Stephanie	Director	-	Direct	Sale	6,333	63.38	$401,385.54	8,000	4
2026-03-05	Almstead, Neil Gregory	Officer	CHIEF TECHNICAL OPS OFFICER	Indirect	Sale	3,989	63.38	$252,822.82	2,737	4
2026-03-05	Golden, Lee Scott	Officer	EVP & CHIEF MEDICAL OFFICER	Direct	Sale	10,000	63.38	$633,800.00	79,944	4
2026-02-19	Boulding, Mark Elliott	Officer	EXEC. VP AND CLO	Direct	Sale	3,019	69.18	$208,854.42	105,212	4
2026-02-18	Golden, Lee Scott	Officer	EVP & CHIEF MEDICAL OFFICER	Direct	Sale	2,484	69.36	$172,290.24	89,944	4
2026-02-18	Gravier, Pierre	Officer	CHIEF FINANCIAL OFFICER	Direct	Sale	2,992	69.36	$207,525.12	87,318	4
2026-02-18	Pauwels, Eric	Officer	CHIEF BUSINESS OFFICER	Direct	Sale	3,019	69.36	$209,397.84	77,122	4
2026-02-18	Almstead, Neil Gregory	Officer	CHIEF TECHNICAL OPS OFFICER	Direct	Sale	3,056	69.36	$211,964.16	112,140	4
2026-02-18	Klein, Matthew B.	Director,Officer	CHIEF EXECUTIVE OFFICER	Direct	Sale	7,371	69.36	$511,252.56	387,082	4
2026-02-18	Utter, Christine Marie	Officer	SVP, CHIEF ACCOUNTING OFFICER	Direct	Sale	2,494	69.36	$172,983.84	70,199	4
2026-02-17	Boulding, Mark Elliott	Officer	EXEC. VP AND CLO	Direct	Sale	2,813	69.71	$196,094.23	111,312	4
2026-01-12	Pauwels, Eric	Officer	CHIEF BUSINESS OFFICER	Direct	Sale	1,024	78.70	$80,588.80	80,141	4
2026-01-09	Boulding, Mark Elliott	Officer	EXEC. VP AND CLO	Direct	Sale	2,314	78.56	$181,787.84	111,312	4
2026-01-08	Almstead, Neil Gregory	Officer	CHIEF TECHNICAL OPS OFFICER	Direct	Sale	881	76.45	$67,352.45	115,196	4
2026-01-08	Utter, Christine Marie	Officer	SVP, CHIEF ACCOUNTING OFFICER	Direct	Sale	1,034	76.45	$79,049.30	72,693	4
2026-01-08	Golden, Lee Scott	Officer	EVP & CHIEF MEDICAL OFFICER	Direct	Sale	866	76.45	$66,205.70	92,428	4
2026-01-08	Klein, Matthew B.	Director,Officer	CHIEF EXECUTIVE OFFICER	Direct	Sale	2,514	76.45	$192,195.30	394,453	4
2026-01-07	Boulding, Mark Elliott	Officer	EXEC. VP AND CLO	Direct	Sale	4,879	77.87	$379,927.73	117,659	4
2026-01-07	Klein, Matthew B.	Director,Officer	CHIEF EXECUTIVE OFFICER	Direct	Sale	3,016	77.48	$233,679.68	396,967	4
2026-01-07	Golden, Lee Scott	Officer	EVP & CHIEF MEDICAL OFFICER	Direct	Sale	642	77.48	$49,742.16	93,294	4
2026-01-07	Almstead, Neil Gregory	Officer	CHIEF TECHNICAL OPS OFFICER	Direct	Sale	1,026	77.48	$79,494.48	116,077	4
2026-01-07	Utter, Christine Marie	Officer	SVP, CHIEF ACCOUNTING OFFICER	Direct	Sale	1,235	77.45	$95,650.75	73,727	4
2026-01-07	Pauwels, Eric	Officer	CHIEF BUSINESS OFFICER	Direct	Sale	1,352	77.48	$104,752.96	87,489	4
2026-01-06	Gravier, Pierre	Officer	CHIEF FINANCIAL OFFICER	Direct	Sale	2,139	76.95	$164,596.05	90,310	4
2026-01-05	Reeve, Emma	Director	-	Direct	Sale	734	76.00	$55,784.00	10,666	4
2026-01-05	Boulding, Mark Elliott	Officer	EXEC. VP AND CLO	Direct	Sale	2,266	75.94	$172,080.04	120,901	4
2026-01-02	Steele, Glenn Jr Md Phd	Director	-	Direct	Sale	12,000	76.35	$916,200.00	18,500	4
2025-12-30	Klein, Matthew B.	Director,Officer	CHIEF EXECUTIVE OFFICER	Direct	Sale	8,089	76.64	$619,940.96	341,875	4
2025-12-19	Pauwels, Eric	Officer	CHIEF BUSINESS OFFICER	Direct	Sale	20,508	77.05	$1,580,141.40	70,373	4
2025-12-18	Pauwels, Eric	Officer	CHIEF BUSINESS OFFICER	Direct	Sale	3,202	75.03	$240,246.06	70,373	4
2025-12-03	Reeve, Emma	Director	-	Direct	Sale	733	78.62	$57,628.46	6,666	4
2025-12-02	Klein, Matthew B.	Director,Officer	CHIEF EXECUTIVE OFFICER	Direct	Sale	3,428	79.07	$271,051.96	349,964	4
2025-11-25	Almstead, Neil Gregory	Officer	CHIEF TECHNICAL OPS OFFICER	Direct	Sale	71,928	83.89	$6,034,039.92	100,625	4
2025-11-25	Jacobson, Allan Steven	Director	-	Direct	Sale	14,199	84.00	$1,192,716.00	17,451	4
2025-11-24	Almstead, Neil Gregory	Officer	CHIEF TECHNICAL OPS OFFICER	Direct	Sale	35,572	80.16	$2,851,451.52	100,625	4
2025-11-21	Reeve, Emma	Director	-	Direct	Sale	10,000	79.50	$795,000.00	6,666	4
2025-11-17	Boulding, Mark Elliott	Officer	EXEC. VP AND CLO	Direct	Sale	2,812	76.45	$214,977.40	103,901	4
2025-11-12	Reeve, Emma	Director	-	Direct	Sale	7,333	74.50	$546,308.50	6,666	4
2025-10-30	Reeve, Emma	Director	-	Direct	Sale	15,666	69.50	$1,088,787.00	6,666	4
2025-10-07	Boulding, Mark Elliott	Officer	EXEC. VP AND CLO	Direct	Sale	3,375	63.89	$215,628.75	103,901	4
2025-10-06	Boulding, Mark Elliott	Officer	EXEC. VP AND CLO	Direct	Sale	2,266	65.07	$147,448.62	103,901	4
2025-10-03	Jacobson, Allan Steven	Director	-	Direct	Sale	12,000	65.00	$780,000.00	17,451	4
2025-10-03	Almstead, Neil Gregory	Officer	CHIEF TECHNICAL OPS OFFICER	Direct	Sale	55,000	66.37	$3,650,350.00	100,625	4
2025-10-03	Reeve, Emma	Director	-	Direct	Sale	25,562	66.02	$1,687,603.24	10,332	4
2025-09-12	Boulding, Mark Elliott	Officer	EXEC. VP AND CLO	Direct	Sale	24,585	61.48	$1,511,485.80	103,901	4
2025-09-11	Reeve, Emma	Director	-	Direct	Sale	15,705	59.50	$934,447.50	10,332	4
2025-09-09	Southwell, David P	Director	-	Direct	Sale	12,000	58.34	$700,080.00	16,850	4
2025-09-08	Pauwels, Eric	Officer	CHIEF BUSINESS OFFICER	Direct	Sale	39,850	56.90	$2,267,465.00	72,912	4
2025-08-28	Jacobson, Allan Steven	Director	-	Direct	Sale	1,667	50.15	$83,600.05	17,451	4
2025-08-15	Boulding, Mark Elliott	Officer	EXEC. VP AND CLO	Direct	Sale	2,813	48.58	$136,655.54	103,901	4
2025-08-05	Klein, Matthew B.	Director,Officer	CHIEF EXECUTIVE OFFICER	Direct	Sale	10,739	51.74	$555,635.86	337,767	4
2025-07-15	Gravier, Pierre	Officer	CHIEF FINANCIAL OFFICER	Direct	Sale	2,516	49.46	$124,441.36	71,920	4
2025-05-16	Boulding, Mark Elliott	Officer	EXEC. VP AND CLO	Direct	Sale	883	46.02	$40,635.66	103,901	4
2025-04-22	Klein, Matthew B.	Director,Officer	CHIEF EXECUTIVE OFFICER	Direct	Sale	2,804	48.74	$136,666.96	273,234	4
2025-04-02	Golden, Lee Scott	Officer	EVP & CHIEF MEDICAL OFFICER	Direct	Sale	897	46.95	$42,114.15	75,997	4
2025-03-17	Pauwels, Eric	Officer	CHIEF BUSINESS OFFICER	Direct	Sale	6,762	56.96	$385,163.52	72,640	4
2025-03-13	Okey, Stephanie	Director	-	Direct	Sale	5,000	54.00	$270,000.00	8,867	4
2025-03-12	Boulding, Mark Elliott	Officer	EXEC. VP AND CLO	Direct	Sale	15,521	53.27	$826,803.67	103,901	4
2025-03-11	Boulding, Mark Elliott	Officer	EXEC. VP AND CLO	Direct	Sale	7,381	53.02	$391,340.62	103,901	4
2025-03-04	Jacobson, Allan Steven	Director	-	Direct	Sale	1,230	51.52	$63,369.60	19,118	4
2025-02-20	Gravier, Pierre	Officer	CHIEF FINANCIAL OFFICER	Direct	Sale	1,167	50.12	$58,490.04	74,436	4
2025-02-20	Utter, Christine Marie	Officer	SVP, CHIEF ACCOUNTING OFFICER	Direct	Sale	878	50.12	$44,005.36	62,564	4
2025-02-20	Pauwels, Eric	Officer	CHIEF EXECUTIVE OFFICER	Direct	Sale	1,567	50.12	$78,538.04	83,860	4
2025-02-20	Boulding, Mark Elliott	Officer	EXEC. VP AND CLO	Direct	Sale	1,614	50.12	$80,893.68	103,901	4
2025-02-20	Klein, Matthew B.	Director,Officer	CHIEF EXECUTIVE OFFICER	Direct	Sale	3,895	50.12	$195,217.40	276,038	4
2025-02-20	Golden, Lee Scott	Officer	EVP & CHIEF MEDICAL OFFICER	Direct	Sale	962	50.12	$48,215.44	76,894	4
2025-02-20	Almstead, Neil Gregory	Officer	CHIEF TECHNICAL OPS OFFICER	Direct	Sale	1,578	50.12	$79,089.36	100,353	4
2025-01-08	Boulding, Mark Elliott	Officer	EXEC. VP AND CLO	Direct	Sale	1,998	44.50	$88,911.00	106,848	4
2025-01-08	Almstead, Neil Gregory	Officer	CHIEF TECHNICAL OPS OFFICER	Direct	Sale	1,552	44.50	$69,064.00	103,231	4
2025-01-08	Klein, Matthew B.	Director,Officer	CHIEF EXECUTIVE OFFICER	Direct	Sale	2,402	44.50	$106,889.00	283,830	4
2025-01-08	Golden, Lee Scott	Officer	EVP & CHIEF MEDICAL OFFICER	Direct	Sale	1,198	44.50	$53,311.00	78,651	4
2025-01-08	Utter, Christine Marie	Officer	SVP, CHIEF ACCOUNTING OFFICER	Direct	Sale	1,662	44.50	$73,959.00	64,321	4
2025-01-08	Pauwels, Eric	Officer	CHIEF EXECUTIVE OFFICER	Direct	Sale	2,136	44.50	$95,052.00	86,805	4
2024-12-31	Klein, Matthew B.	Director,Officer	CHIEF EXECUTIVE OFFICER	Direct	Sale	8,279	45.16	$373,879.64	217,528	4
2024-12-03	Boulding, Mark Elliott	Officer	EXEC. VP AND CLO	Direct	Sale	10,308	53.50	$551,478.00	92,389	4
2024-12-02	Utter, Christine Marie	Officer	SVP, CHIEF ACCOUNTING OFFICER	Direct	Sale	17,800	51.89	$923,642.00	52,428	4
2024-12-02	Zeldis, Jerome B	Director	-	Direct	Sale	24,000	51.64	$1,239,360.00	14,500	4
2024-12-02	Almstead, Neil Gregory	Officer	CHIEF TECHNICAL OPS OFFICER	Direct	Sale	69,550	52.32	$3,638,856.00	86,202	4
2024-07-16	Gravier, Pierre	Officer	CHIEF FINANCIAL OFFICER	Direct	Sale	2,269	34.02	$77,191.38	53,531	4
2024-05-22	Zeldis, Jerome B	Director	-	Direct	Sale	20,000	38.24	$764,800.00	14,500	4
2024-05-07	Golden, Lee Scott	Officer	EVP & CHIEF MEDICAL OFFICER	Direct	Sale	175	32.82	$5,743.50	59,813	4
2024-04-19	Klein, Matthew B.	Director,Officer	CHIEF EXECUTIVE OFFICER	Direct	Sale	3,361	24.89	$83,655.29	225,807	4
2024-04-17	Pauwels, Eric	Director,Officer	CHIEF EXECUTIVE OFFICER	Direct	Sale	787	25.14	$19,785.18	67,694	4
2024-04-17	Klein, Matthew B.	Director,Officer	CHIEF EXECUTIVE OFFICER	Direct	Sale	1,307	25.14	$32,857.98	229,168	4
2024-04-02	Golden, Lee Scott	Officer	EVP & CHIEF MEDICAL OFFICER	Direct	Sale	526	28.37	$14,922.62	59,988	4
2024-01-30	Almstead, Neil Gregory	Officer	CHIEF TECHNICAL OPS OFFICER	Direct	Sale	618	27.25	$16,840.50	61,202	4
2024-01-30	Pauwels, Eric	Officer	CHIEF BUSINESS OFFICER	Direct	Sale	366	27.25	$9,973.50	44,181	4
2024-01-30	Utter, Christine Marie	Officer	SVP, CHIEF ACCOUNTING OFFICER	Direct	Sale	318	27.25	$8,665.50	35,528	4
2024-01-30	Boulding, Mark Elliott	Officer	EXEC. VP AND CLO	Direct	Sale	794	27.25	$21,636.50	71,189	4
2024-01-22	Jacobson, Allan Steven	Director	-	Direct	Sale	10,000	27.38	$273,800.00	12,348	4
2024-01-09	Boulding, Mark Elliott	Officer	EXEC. VP AND CLO	Direct	Sale	1,938	29.01	$56,221.38	71,983	4
2024-01-09	Klein, Matthew B.	Director,Officer	CHIEF EXECUTIVE OFFICER	Direct	Sale	5,443	29.01	$157,901.43	160,475	4
2024-01-09	Golden, Lee Scott	Officer	CHIEF MEDICAL OFFICER	Direct	Sale	1,225	29.01	$35,537.25	37,914	4
2024-01-09	Pauwels, Eric	Officer	CHIEF BUSINESS OFFICER	Direct	Sale	2,065	29.01	$59,905.65	44,547	4
2024-01-09	Utter, Christine Marie	Officer	SVP, FINANCE & CAO	Direct	Sale	1,653	29.01	$47,953.53	35,846	4
2024-01-09	Almstead, Neil Gregory	Officer	CHIEF TECHNICAL OPS OFFICER	Direct	Sale	1,521	29.01	$44,124.21	61,820	4
2024-01-08	Schmertzler, Michael	Director	-	Direct	Sale	1,500	27.81	$41,715.00	115,266	4
2024-01-05	Klein, Matthew B.	Director,Officer	CHIEF EXECUTIVE OFFICER	Direct	Sale	10,107	27.15	$274,405.05	168,155	4
2023-12-12	Gravier, Pierre	Officer	CHIEF FINANCIAL OFFICER	Direct	Purchase	7,700	25.81	$198,737.00	33,700	4
2023-09-06	Young, Alethia	Director	-	Direct	Sale	11,666	39.84	$464,773.44	9,067	4
Additional insider transactions are for subscribers only. Unlock the complete Form 4 filing history Start 7-day free trial

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Institutional Ownership

No data available for chart

2026-03-31

112.22%

Inst. Shares: 92,608,246

Shares Outstanding: 82,521,023

2025-12-31

111.11%

Inst. Shares: 88,367,695

Shares Outstanding: 79,534,290

2025-09-30

102.65%

Inst. Shares: 80,551,152

Shares Outstanding: 78,471,119

2025-06-30

99.05%

Inst. Shares: 77,405,857

Shares Outstanding: 78,151,240

2025-03-31

98.60%

Inst. Shares: 77,025,624

Shares Outstanding: 78,115,836

Date	Institutional Shares Owned	Shares Outstanding	Institutional Ownership %
2026-03-31	92,608,246	82,521,023	112.22%
2025-12-31	88,367,695	79,534,290	111.11%
2025-09-30	80,551,152	78,471,119	102.65%
2025-06-30	77,405,857	78,151,240	99.05%
2025-03-31	77,025,624	78,115,836	98.60%
2024-12-31	72,340,607	76,845,055	94.14%
2024-09-30	73,213,641	76,925,523	95.17%
2024-06-30	74,784,308	76,725,070	97.47%
2024-03-31	78,218,516	76,496,127	102.25%
2023-12-31	73,702,928	74,838,392	98.48%
2023-09-30	74,688,506	75,377,997	99.09%
2023-06-30	72,533,054	74,730,433	97.06%
Additional institutional holders are for subscribers only. Unlock the complete Form 13F ownership history Start 7-day free trial

PTC THERAPEUTICS, INC. (PTCT) — SEC Financial Statements & Analysis

PTC THERAPEUTICS, INC. (PTCT) is a pharmaceutical preparations company, incorporated in DE. PTC THERAPEUTICS, INC. trades on Nasdaq as: PTCT. Based on its latest SEC filing (Form 10-Q, period ending 2026-06-30), PTC THERAPEUTICS, INC. reported a -42.84% year-over-year revenue growth, a Debt-to-Equity ratio of -20.66x, a Price-to-Sales (P/S) ratio of 6.71x (TTM), a Price-to-Book (P/B) ratio of -40.95x (TTM), at a market cap of $6.77B. Figures below are sourced from SEC EDGAR, as-filed.

Net Revenue TTM Growth 1Y: -42.84%
Debt To Equity: -20.66x
P/S TTM: 6.71x
P/B TTM: -40.95x
Market Cap: $6.77B

Data as of 2026-06-30 · Source: SEC EDGAR

Frequently Asked Questions

What industry is PTC THERAPEUTICS, INC. in?

PTC THERAPEUTICS, INC. (PTCT) operates in the Pharmaceutical Preparations industry.

What is PTCT's market cap?

PTC THERAPEUTICS, INC. (PTCT) has a market capitalization of $6.77B as of 2026-06-30.

What exchange does PTCT trade on?

PTC THERAPEUTICS, INC. (PTCT) trades on the Nasdaq.

Where is PTC THERAPEUTICS, INC. incorporated?

PTC THERAPEUTICS, INC. is incorporated in DE.